

NCT ID	NCT06835179
Title	SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
Phase	Phase 2
Date Added	2025-02-19
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp

NCT ID	NCT06841159
Title	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) Combined With Anti-PD1?Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2025-03-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp

NCT ID	NCT06850103
Title	SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases
Phase	Phase 2
Date Added	2025-03-25
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp

NCT ID	NCT06856837
Title	– IKF/AIO-QUINTIS – Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Phase	Phase 2
Date Added	2025-03-04
Location	Austria Germany
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp

NCT ID	NCT06764680
Title	Oral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Phase	Phase 2

Date Added	2025-01-08
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06412198
Title	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase	Phase 1, Phase 2
Date Added	2024-05-14
Location	Massachusetts, United States Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Adagrasib, cemiplimab, cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT06415851
Title	Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Phase	Phase 2
Date Added	2024-05-15
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06455254
Title	Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
Phase	Phase 2
Date Added	2024-06-12
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05726864
Title	A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2023-02-14

Location	Arizona, United States
	California, United States
	Colorado, United States
	Florida, United States
	Georgia, United States
	Iowa, United States
	Louisiana, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	New York, United States
	Pennsylvania, United States
	Tennessee, United States
	Texas, United States
	Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ELI-002 7P
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05768503
Title	Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase	Phase 3
Date Added	2023-03-14
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Control Rx, Experimental drug
Tags	MSS/ MMRp